What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Immune system
James G. Krueger mainly investigates Immunology, Psoriasis, Immune system, Interleukin 17 and Tumor necrosis factor alpha.
Immunology is closely attributed to Disease in his work.
James G. Krueger interconnects Surgery, Internal medicine, Risankizumab and Keratinocyte in the investigation of issues within Psoriasis.
His work in Keratinocyte addresses subjects such as Dermis, which are connected to disciplines such as Molecular biology.
His Immune system research includes themes of Myeloid and Genetic predisposition.
His Interleukin 17 research is multidisciplinary, relying on both Interleukin, Interleukin 22, Keratin 16 and Interferon gamma.
His most cited work include:
- Pathogenesis and therapy of psoriasis (1274 citations)
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis (826 citations)
- Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. (791 citations)
What are the main themes of his work throughout his whole career to date?
Immunology, Psoriasis, Atopic dermatitis, Immune system and Pathology are his primary areas of study.
Immunology is frequently linked to Disease in his study.
James G. Krueger has researched Psoriasis in several fields, including Tumor necrosis factor alpha, Internal medicine and Interleukin 17.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Endocrinology and Oncology.
His research on Immune system focuses in particular on Dendritic cell.
His Pathology study often links to related topics such as Keratinocyte.
He most often published in these fields:
- Immunology (48.95%)
- Psoriasis (45.47%)
- Atopic dermatitis (19.69%)
What were the highlights of his more recent work (between 2018-2021)?
- Psoriasis (45.47%)
- Immunology (48.95%)
- Atopic dermatitis (19.69%)
In recent papers he was focusing on the following fields of study:
James G. Krueger mostly deals with Psoriasis, Immunology, Atopic dermatitis, Internal medicine and Dermatology.
His study focuses on the intersection of Psoriasis and fields such as Interferon with connections in the field of Tyrosine kinase 2.
His Immune system, Cytokine, Dendritic cell, Chemokine and Filaggrin study are his primary interests in Immunology.
His Atopic dermatitis research incorporates elements of Biomarker, T cell, Systemic inflammation and SCORAD.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Oncology.
In his study, Adalimumab and Brodalumab is inextricably linked to Hidradenitis suppurativa, which falls within the broad field of Dermatology.
Between 2018 and 2021, his most popular works were:
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis (152 citations)
- Atopic dermatitis endotypes and implications for targeted therapeutics. (122 citations)
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. (69 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Cancer
His primary areas of study are Immunology, Atopic dermatitis, Psoriasis, Internal medicine and Inflammation.
His works in Cytokine, Immune system, Dendritic cell, Interleukin and Filaggrin are all subjects of inquiry into Immunology.
James G. Krueger has included themes like Immunohistochemistry, SCORAD, Disease, Biomarker and Immunoglobulin E in his Atopic dermatitis study.
James G. Krueger studies Psoriasis Area and Severity Index which is a part of Psoriasis.
His Internal medicine research focuses on subjects like Gastroenterology, which are linked to Area under the curve and Keratin 16.
The study incorporates disciplines such as Skin biopsy, Endothelium and Pathogenesis in addition to Inflammation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
